Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin) - Top-Institutions - MDSpire

Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

  • By

  • Emma Guttman-Yassky

  • Alan D. Irvine

  • Melinda Gooderham

  • Stephan Weidinger

  • Lynda Spelman

  • Jonathan I. Silverberg

  • Heidi Crane

  • Hany ElMaraghy

  • Louise DeLuca-Carter

  • Maria Lucia Buziqui Piruzeli

  • Georgia Martimianaki

  • Evangeline Pierce

  • Helena Agell

  • Diamant Thaçi

  • June 19, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount Sinai

    New York, New York

    Key Differentiators

    • Dermatology

  • #2

    Oregon Health & Science University
    Oregon Health & Science University

    Portland, Oregon

    Key Differentiators

    • Dermatology

Original Source(s)

Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

  • by Emma Guttman-Yassky, Alan D. Irvine, Melinda Gooderham, Stephan Weidinger, Lynda Spelman, Jonathan I. Silverberg, Heidi Crane, Hany ElMaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Georgia Martimianaki, Evangeline Pierce, Helena Agell, Diamant Thaçi

  • June 19, 2026

Related Content

Editorial: Type 2 inflammatory skin diseases: novel therapies and clinical insights

IL-17, IL-23 Therapies Lead Psoriasis Care

Network meta-analysis suggests higher PASI 90 response rates with biologics vs oral systemic therapies

The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa—A Narrative Review